日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma

吉西他滨联合白蛋白紫杉醇加奈库帕尼或安慰剂治疗未经治疗的转移性胰腺导管腺癌的随机II期临床试验

O'Reilly, Eileen M; Barone, Diletta; Mahalingam, Devalingam; Bekaii-Saab, Tanios; Shao, Spencer H; Wolf, Julie; Rosano, Molly; Krause, Silva; Richards, Donald A; Yu, Kenneth H; Roach, James M; Flaherty, Keith T; Ryan, David P

Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects.

在健康受试者中,阿达木单抗生物类似药(M923)与阿达木单抗(Humira)具有药代动力学等效性、可比安全性和免疫原性

Hillson Jan, Mant Tim, Rosano Molly, Huntenburg Carolyn, Alai-Safar Mehrshid, Darne Siddhesh, Palmer Donna, Pavlova Borislava G, Doralt Jennifer, Reeve Russell, Goel Niti, Weilert Doris, Rhyne Paul W, Chance Kamali, Caminis John, Roach James, Ganguly Tanmoy

Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results

奈库帕尼联合白蛋白紫杉醇和吉西他滨治疗转移性胰腺癌患者的安全性、药代动力学、药效学和抗肿瘤活性:I期临床试验结果

O'Reilly, Eileen M; Roach, James; Miller, Paul; Yu, Kenneth H; Tjan, Catherine; Rosano, Molly; Krause, Silva; Avery, William; Wolf, Julie; Flaherty, Keith; Nix, Darrell; Ryan, David P